SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Drug Development
Why Biogen Spinoff Bioverativ’s Anemia Drug Could Be A Blockbuster
July 11, 2017
 · 
1 min read
Genetown
Liver Safety Issues Lead The EMA To Restrict Biogen’s MS Drug
July 10, 2017
 · 
1 min read
Why This Biotech, Up 300% Since May, Could be the Next Big M&A Target
Deals
What Makes Biogen and Bristol-Myers Squibb Such Attractive Takeover Targets
June 27, 2017
 · 
3 min read
Genetown
Alzheimer’s Drug Leads UBS To Upgrade Biogen
June 21, 2017
 · 
1 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Business
Biogen Brings Ex-Shire Exec Into C-Suite
June 20, 2017
 · 
2 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Deals
What Biogen CFO’s Departure Means for Company’s M&A Strategy
June 15, 2017
 · 
2 min read
Alexion is Under Investigation by the HHS Office of Inspector General
Business
Alexion Poaches Biogen’s Longtime CFO
June 14, 2017
 · 
2 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
BioCapital
What Biogen Wants in Return for Financial Assistance of Its $750,000 a Year Drug
June 12, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Business
Biogen Loses Yet Another Top Exec
May 26, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
 · 
3 min read
Press Releases
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
May 14, 2026
 · 
8 min read
Press Releases
Biogen Completes Acquisition of Apellis Pharmaceuticals
May 14, 2026
 · 
21 min read
Press Releases
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026
 · 
11 min read
Press Releases
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026
 · 
18 min read
Press Releases
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026
 · 
14 min read
Press Releases
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting
April 9, 2026
 · 
10 min read
Press Releases
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
April 7, 2026
 · 
3 min read
Press Releases
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
 · 
32 min read
Press Releases
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026
 · 
13 min read
Load More